On April 30, 2024 Mythic Therapeutics, a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, reported the publication of preclinical data highlighting the differentiating properties of its investigational cMET-targeting ADC, MYTX-011, in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) (Press release, Mythic Therapeutics, APR 30, 2024, View Source;utm_medium=rss&utm_campaign=mythic-therapeutics-announces-publication-of-preclinical-data-highlighting-the-differentiating-properties-of-mytx-011-in-molecular-cancer-therapeutics [SID1234642466]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The potential of novel ADC technologies to enhance payload delivery to tumors is relatively underexplored compared to advances in linker-payload technology and target selection," said Nimish Gera, Ph.D., lead author of the paper and Scientific Co-founder, Vice President of Biologics at Mythic. "We believe that engineering pH-dependent binding could be a particularly compelling strategy for ADCs targeting medium to low levels of cMET expression in patients. We’re pleased to publish this study illustrating how the properties of MYTX-011, including its potential for increased on-target potency, enhanced tolerability, longer half-life and higher efficacy, may enable this therapy to serve patients with a broad range of cMET expression who otherwise have limited treatment options. We look forward to continuing to evaluate MYTX-011 in our ongoing Phase 1 clinical trial."
The study demonstrated that incorporation of pH-dependent binding in the antibody component of a cMET targeting ADC can overcome the requirement for high cMET expression on tumors, an innovation that has the potential to benefit a broader population of patients with lower cMET levels. MYTX-011 drove four-fold higher net internalization than a non-pH engineered parent ADC in non-small cell lung cancer (NSCLC) cells and showed increased cytotoxicity against a panel of cell lines from various solid tumors, including head and neck, gastric, pancreatic, esophageal, bladder, kidney and skin cancer. A single dose of MYTX-011 showed at least three-fold higher efficacy than a benchmark ADC in mouse xenograft models of NSCLC ranging from low to high cMET expression. Additionally, MYTX-011 showed improved pharmacokinetics over parent and benchmark ADCs. In a repeat dose toxicology study, MYTX-011 exhibited a toxicity profile similar to other MMAE-based ADCs.
MYTX-011 is currently being evaluated in the Phase 1 KisMET-01 clinical trial, a first-in-human, open-label, multi-center, dose escalation and dose expansion study enrolling patients with locally advanced, recurrent or metastatic NSCLC (NCT05652868).
About MYTX-011
MYTX-011, an investigational cMET-targeting antibody-drug conjugate (ADC), leverages Mythic’s innovative FateControl technology, which allows ADCs to actively navigate inside of cells, potentially increasing delivery of anti-cancer agents to tumor cells with less impact on healthy cells. This breakthrough approach takes the next step beyond linker-payload technologies and is designed to improve ADC efficacy against a broad set of molecular targets and patient profiles. MYTX-011 is currently being evaluated in the Phase 1 KisMET-01 clinical trial, a first-in-human, open-label, multi-center, dose escalation and dose expansion study enrolling patients with locally advanced, recurrent or metastatic NSCLC (NCT05652868).